MarketPulse

BRAF V600E mutation

2 articles
BenzingaBenzinga··Vandana Singh

Pfizer's Braftovi Combination Therapy Receives Full FDA Approval for BRAF-Mutated Colorectal Cancer

Pfizer's Braftovi receives full FDA approval for treating BRAF-mutated metastatic colorectal cancer when combined with cetuximab and chemotherapy, based on Phase 3 trial data.
PFEFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

Pfizer's Braftovi Regimen Achieves Primary Endpoints in Metastatic Colorectal Cancer Trial

Pfizer's Braftovi regimen met primary endpoints in Phase 3 colorectal cancer trial, showing significant improvements in progression-free survival versus standard chemotherapy in BRAF-mutated patients.
PFEFDLPJPcolorectal cancerBraftovi